24 Nov The geko™ device receives UK reimbursement
We are pleased to share that the geko device is now reimbursed in the UK, enabling clinicians to make a recommendation to the relevant approval committee within their local Integrated Care System (ICS) that the device should be considered for local formulary inclusion.
In turn, reimbursement for the geko device will help the 5.3 million people in the UK who live with venous leg ulcers (VLUs) access an adjunctive method of care to help with wound healing, delivering new hope to these patients with hard-to-heal chronic wounds.
Improving patient outcomes and delivery of care
To achieve reimbursement, products must demonstrate safety and quality as well as a positive impact on patient outcomes and the ability to reduce the total costs within the patient pathway. The geko device demonstrated improved clinical outcomes, released significant clinician time and delivered real economic and environmental value to the wound management system.
This news follows the publication of our randomised self-controlled trial (RCT) earlier this year, which demonstrated geko device efficacy for accelerating venous leg ulcer (VLU) healing by more than double when used alongside standard of care versus standard of care alone.
Ideal for home use and easy-to-fit, the geko device is a seamless addition to the current VLU pathway, empowering patients to both self-care, without disruption to daily routines, and to share their care with family members and wound care professionals, reinforced by the high concordance rate of 94% reported in our RCT. Independent health economic modelling also demonstrates the geko device is cost saving.
Demonstrating economic impact
Richard Tuson, Health Analytical Solutions Ltd (HAS), independently examined the economic outcome of the clinical trial data and the subsequent real-world use of the geko device in this wound population. Tuson commented: “Venous leg ulcers are a growing burden, most often caused by compromised venous return. Worldwide, the annual costs for managing and treating VLUs is rising, and in Australia, France, Germany, Italy, Spain, the UK and USA the spend ranges from $0.24 billion (France) to $4.94 billion (US) and totalled US$10.73 billion in the geographies analysed.”
HAS also led the successful application for UK reimbursement, enabling wound care professionals to now prescribe the geko device, from 1st November 2023.
Our CEO, Bernard Ross, summarised: “This is a key milestone for our business and for our global wound franchise specifically. Securing UK reimbursement is a major step towards helping the one in 50 people in the UK suffering with chronic wounds to access a treatment that accelerates the rate of healing, particularly in wounds that struggle to heal with standard of care alone and represent the highest patient cost. It also cements our commitment to the streamlining of wound care through evidence-based clinical and economic efficiency for better patient outcomes and quality of life.”
Read the full news story here.
To find out how to access the geko device, click here.